| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JNK-9L | GDSC1000 | pan-cancer | AAC | 0.21 | 4e-07 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-06 |
| mRNA | YM201636 | GDSC1000 | pan-cancer | AAC | 0.17 | 5e-06 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.18 | 6e-06 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | 0.15 | 2e-05 |
| mRNA | Obatoclax Mesylate | GDSC1000 | pan-cancer | AAC | 0.17 | 2e-05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 3e-05 |
| mRNA | Mitomycin-C | GDSC1000 | pan-cancer | AAC | 0.17 | 4e-05 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | 0.17 | 5e-05 |